Man Group plc Raises Stock Position in Charles River Laboratories International, Inc. (NYSE:CRL)

Man Group plc increased its position in Charles River Laboratories International, Inc. (NYSE:CRL - Free Report) by 359.4% during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 82,390 shares of the medical research company's stock after purchasing an additional 64,456 shares during the period. Man Group plc owned approximately 0.16% of Charles River Laboratories International worth $15,209,000 at the end of the most recent reporting period.

Other institutional investors also recently bought and sold shares of the company. Vanguard Group Inc. lifted its stake in shares of Charles River Laboratories International by 1.0% in the fourth quarter. Vanguard Group Inc. now owns 6,158,926 shares of the medical research company's stock worth $1,136,938,000 after buying an additional 60,497 shares in the last quarter. Wellington Management Group LLP lifted its position in Charles River Laboratories International by 9.0% in the 4th quarter. Wellington Management Group LLP now owns 4,076,426 shares of the medical research company's stock valued at $752,508,000 after acquiring an additional 335,658 shares in the last quarter. Allspring Global Investments Holdings LLC lifted its position in Charles River Laboratories International by 2.7% in the 4th quarter. Allspring Global Investments Holdings LLC now owns 1,808,002 shares of the medical research company's stock valued at $330,231,000 after acquiring an additional 47,221 shares in the last quarter. Geode Capital Management LLC boosted its stake in Charles River Laboratories International by 1.2% during the 4th quarter. Geode Capital Management LLC now owns 1,233,211 shares of the medical research company's stock valued at $227,042,000 after purchasing an additional 14,787 shares during the last quarter. Finally, Ariel Investments LLC increased its holdings in shares of Charles River Laboratories International by 18.9% in the 4th quarter. Ariel Investments LLC now owns 1,067,327 shares of the medical research company's stock worth $197,029,000 after purchasing an additional 169,640 shares in the last quarter. 98.91% of the stock is owned by hedge funds and other institutional investors.

Charles River Laboratories International Stock Performance

CRL traded down $0.07 during trading on Friday, hitting $135.53. The company's stock had a trading volume of 123,209 shares, compared to its average volume of 986,076. The business's 50 day simple moving average is $132.85 and its 200-day simple moving average is $163.81. The firm has a market cap of $6.66 billion, a PE ratio of 904.03, a P/E/G ratio of 4.54 and a beta of 1.50. Charles River Laboratories International, Inc. has a one year low of $91.86 and a one year high of $254.15. The company has a quick ratio of 1.14, a current ratio of 1.41 and a debt-to-equity ratio of 0.65.

Charles River Laboratories International (NYSE:CRL - Get Free Report) last announced its earnings results on Wednesday, May 7th. The medical research company reported $2.34 EPS for the quarter, topping analysts' consensus estimates of $2.06 by $0.28. The company had revenue of $984.17 million for the quarter, compared to analysts' expectations of $942.34 million. Charles River Laboratories International had a return on equity of 14.69% and a net margin of 0.52%. Charles River Laboratories International's revenue for the quarter was down 2.7% compared to the same quarter last year. During the same period last year, the firm earned $2.27 EPS. As a group, sell-side analysts predict that Charles River Laboratories International, Inc. will post 9.36 EPS for the current fiscal year.

Analyst Ratings Changes

A number of research analysts have recently issued reports on CRL shares. Redburn Atlantic raised Charles River Laboratories International from a "neutral" rating to a "buy" rating and lowered their price target for the company from $188.00 to $182.00 in a report on Friday. Citigroup raised Charles River Laboratories International from a "sell" rating to a "neutral" rating and boosted their target price for the stock from $155.00 to $175.00 in a research report on Tuesday, March 4th. JPMorgan Chase & Co. dropped their price target on shares of Charles River Laboratories International from $175.00 to $165.00 and set a "neutral" rating on the stock in a report on Thursday, February 20th. Evercore ISI upgraded shares of Charles River Laboratories International from an "in-line" rating to an "outperform" rating and set a $170.00 price target for the company in a research note on Thursday, May 8th. Finally, The Goldman Sachs Group cut shares of Charles River Laboratories International from a "buy" rating to a "neutral" rating and decreased their price objective for the company from $190.00 to $170.00 in a report on Friday, March 21st. One research analyst has rated the stock with a sell rating, thirteen have assigned a hold rating and four have issued a buy rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of "Hold" and a consensus price target of $171.85.

Insider Activity at Charles River Laboratories International

In other Charles River Laboratories International news, EVP Joseph W. Laplume sold 500 shares of the firm's stock in a transaction that occurred on Tuesday, May 13th. The shares were sold at an average price of $145.41, for a total transaction of $72,705.00. Following the sale, the executive vice president now owns 19,513 shares in the company, valued at approximately $2,837,385.33. This trade represents a 2.50% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. 1.30% of the stock is currently owned by corporate insiders.

Charles River Laboratories International Profile

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).